Physician profile
Charles K Moore
NPI 1699795641
$47,269.57
in general payments reported to CMS, 2019-2025
36 companies · $22.20 in 2025
The $22.20 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $17K · 2020: $7,355 · 2021: $6,192 · 2022: $5,348 · 2023: $11K · 2024: $681 · 2025: $22.20.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $9,175 · Food and Beverage: $2,103 · Travel and Lodging: $235.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $9,175.00 |
| Food and Beverage | $2,103.18 |
| Travel and Lodging | $234.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $40,469.20 | 2019-2024 | |
| Abiomed | $1,627.60 | 2019-2023 | Impella |
| Novartis Pharmaceuticals Corporation | $516.26 | 2019-2024 | |
| Janssen Pharmaceuticals, INC | $472.52 | 2019-2024 | Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $400.12 | 2019-2024 | Jardiance |
| Actelion Pharmaceuticals US, INC. | $380.99 | 2020-2024 | Uptravi, Opsumit |
| E.R. Squibb & Sons, L.L.C. | $366.74 | 2019-2024 | Camzyos |
| Cvrx, INC. | $264.27 | 2023-2024 | Barostim Neo System |
| Merck Sharp & Dohme LLC | $260.98 | 2021-2024 | Verquvo |
| Bayer Healthcare Pharmaceuticals INC. | $255.98 | 2019-2023 | |
| Livanova USA, INC. | $238.97 | 2022 | |
| Amgen INC. | $228.54 | 2019-2022 | |
| United Therapeutics Corporation | $192.55 | 2019-2024 | Remodulin, Orenitram, Tyvaso |
| Astrazeneca Pharmaceuticals LP | $161.79 | 2019-2023 | Brilinta |
| Vifor Pharma, INC. | $152.99 | 2019-2020 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $143.38 | 2023-2024 | |
| Medtronic Vascular, INC. | $137.62 | 2019 | |
| Daxor Corporation | $129.58 | 2022 | |
| Abbott Laboratories | $128.79 | 2020-2024 | Thoratec Heartmate 3 Lvas Implant Kit |
| Astellas Pharma US INC | $124.19 | 2019 | |
| Irhythm Technologies, INC. | $112.77 | 2019-2023 | Zio Xt Patch |
| Gilead Sciences, INC. | $108.49 | 2019 | |
| Impulse Dynamics (USA) INC. | $100.01 | 2021-2023 | Optimizer |
| Nuwellis, INC. | $48.51 | 2021 | |
| Akcea Therapeutics, INC. | $43.85 | 2019-2020 | |
| Dendreon Pharmaceuticals LLC | $31.42 | 2024 | Provenge |
| Scpharmaceuticals INC. | $30.44 | 2024 | |
| Lantheus Medical Imaging, INC. | $23.15 | 2019 | |
| Integra Lifesciences Corporation | $22.20 | 2025 | Integra, Integra Dermal Regeneration Template, Primatrix |
| Blue Earth Diagnostics | $20.74 | 2023 | |
| Biotronik INC. | $16.60 | 2019 | |
| Chiesi USA, INC. | $16.39 | 2023 | Cleviprex, Kengreal |
| Tolmar, INC. | $15.82 | 2023 | |
| Lexicon Pharmaceuticals, INC. | $14.57 | 2024 | |
| Ge Healthcare | $11.55 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charles Moore listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.